Wall Street expects a year-over-year increase in earnings on higher revenues when Myriad Genetics (MYGN) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock ma ...

SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. Of those diagnosed with anxiety and/or depression, half (50%) said they have lost years of their lifetime b ...

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad's prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA laboratories have reported a broad range of PPV for the 2 ...

Myriad Genetics, Inc. (MYGN) recently announced results from a multi-year, real-world study that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight Psychotropic test. The study consisted of nearly 21,000 patients.Management expects to share additional study results later in 2024.The study’s latest positive initial outcome is a significant stepping stone for Myriad Genetics and is likely to boost the usage of its GeneSight Psychotropic test, part of i ...

Myriad Genetics (MYGN) is well poised for growth in the coming quarters, backed by strong improvement in testing volume across all its businesses. Strong solvency is an added advantage. Yet, foreign exchange headwinds and stiff competition are a concern.In the past six months, this Zacks Rank #3 (Hold) stock has gained 32.8% compared with a 0.6% rise of the industry and a 20% rise of the S&P 500 composite.The renowned genetic testing and precision medicine company has a market capitalization of $1.83 billio ...

SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test. "We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSi ...

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad's foundational and proprietary method of preparing cell free DNA. This method ...

SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad's SneakPeek Snap® products in the U.S through 2040. The patent fu ...

Myriad Genetics, Inc. (MYGN) reported an adjusted earnings per share (EPS) of 4 cents per share in the fourth quarter of 2023 versus the year-ago quarter’s loss of 12 cents. The metric surpassed the Zacks Consensus Estimate of 2 cents by 100%.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.The GAAP loss was 36 cents compared with the prior-year quarter’s loss of 52 cents.For the full year, the adjusted loss was 27 cen ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President & Chief Executive Officer Mark Verratti - Chief Commercial Officer Sam Raha - Chief Operating Officer Scott Leffler - Chief Financial Officer Conference Call Participants Andrew Cooper - Raymond James Prashant Kota - Goldman Sachs Jack Meehan - Nephron Research David Westenberg - Piper Sandler Mason Carrico - Steph ...